Srinivas Akkaraju net worth and biography

Srinivas Akkaraju Biography and Net Worth

Director of Scholar Rock

Dr. Srinivas Akkaraju has served as a member of our board of directors since July 2022. Dr. Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from 2013 to 2016, he served as a General Partner of Sofinnova Ventures. Prior to that, he served as Managing Director of New Leaf Venture Partners. Earlier, he served as a Managing Director and Co-Founder at Panorama Capital, LLC, a private equity firm. Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group. Dr. Akkaraju received a M.D. and Ph.D. in Immunology from Stanford University. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University.

What is Srinivas Akkaraju's net worth?: The estimated net worth of Srinivas Akkaraju is at least $31.27 million as of November 26th, 2025. Dr. Akkaraju owns 691,797 shares of Scholar Rock stock worth more than $31,269,224 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Akkaraju may own. Learn More about Srinivas Akkaraju's net worth.
How do I contact Srinivas Akkaraju?: The corporate mailing address for Dr. Akkaraju and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at [email protected]. Learn More on Srinivas Akkaraju's contact information.
Has Srinivas Akkaraju been buying or selling shares of Scholar Rock?: Within the last three months, Srinivas Akkaraju has bought $18,807,336.03 of Scholar Rock stock. Most recently, on Monday, October 6th, Srinivas Akkaraju bought 113,025 shares of Scholar Rock stock. The stock was acquired at an average cost of $38.65 per share, with a total value of $4,368,416.25. Following the completion of the transaction, the director now directly owns 500,439 shares of the company's stock, valued at $19,341,967.35. Learn More on Srinivas Akkaraju's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Kristina Burow (Director), Jeffrey Flier (Director), Michael Gilman (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), Joshua Reed (Director), Tracey Sacco (Chief Commercial Officer), and Akshay Vaishnaw (President, R&D). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, Scholar Rock insiders bought shares 2 times. They purchased a total of 500,439 shares worth more than $18,807,336.03. In the last year, insiders at the sold shares 24 times. They sold a total of 405,963 shares worth more than $14,753,847.01. The most recent insider tranaction occured on October, 6th when Director Srinivas Akkaraju bought 113,025 shares worth more than $4,368,416.25. Insiders at Scholar Rock own 13.3% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 10/6/2025.

Srinivas Akkaraju Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2025	Buy	113,025	$38.65	$4,368,416.25	500,439
10/3/2025	Buy	387,414	$37.27	$14,438,919.78	387,414
10/7/2024	Sell	1,175,713	$29.25	$34,389,605.25	5,612,896

Srinivas Akkaraju Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $45.20

$42.83

$45.50

50 Day Range

MA: $34.97

$27.92

$45.20

2 Week Range

Now: $45.20

$22.71

$46.98

Volume

1,340,235 shs

Average Volume

2,069,553 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61